Joseph Stringer: Okay. Great. Yes. Thanks for all that color. I guess maybe just moving on to the new platform. So, you are launching some upgraded platforms to your legacy. Your legacy devices, I think you said that they have been shipped to a certain number of countries. And so I just wanted to maybe get some info there, maybe some early feedback from some of your customers who have used these new platforms. As well as I think you said previously that the new body tight and face tight, the upgrades kind of lower the procedure complexity. So, I was also curious if maybe you have been selling more to anybody that’s I guess not a plastic surgeon, so like health clinics or anything like that, and if they found the new platform easy to use?
Moshe Mizrahy: Absolutely. Let me start with the Ignite, okay. The Ignite is the full surgical platform. What do I mean by full surgical platform, the Ignite can handle the body type, the face type, what we call the first generation, but with higher energy because we improve the hand pieces. But that’s something that we did in order to ease the process and make the treatment faster. In addition, we have developed new hand pieces which instead of two cannulas, they have only one cannula and the bipolar RF is on the tip of the cannula. That make the doctor more flexible to reach any part in the body, much easier than with the regular our sale. In addition to that, these platforms will include two new Morpheus hand pieces, one for the face and one for the body.
And also the Morpheus, it’s the Morpheus which call now Morpheus8 Burst is a new generation technology. You can go any depth you want. You can pulse in any depth up to three in every punch of the skin. You can determine the level of energy in every depth. So, for example, you can go to 7 millimeter, deliver 50% of the energy, go up to 5 millimeter, deliver 30% of the energy and go up to 2 millimeter deep in the skin and deliver 20% or together 100%. So, this is another technology that we develop. And the Morpheus8 Burst hand pieces for the face and for the body with 24 pins or with 40 pins are able to use these two technologies which we call burst and scale. So, this is one platform, which we believe that it’s a break – it’s a breakthrough technology.
It’s something that nobody did before. Well protected because all covered with patent which now we can count on 25 years. Although I have to say, that nobody have tried to infringe our radiofrequency-assisted lipolysis, the body type pattern since the beginning of the – since the beginning of 2026, when we start promoting them and commercializing them in the United States. The second platform is the Optimus Max. Basically the Optimus Max, it’s a new design, much nicer than the regular Optimas with adjustable screen, with hand pieces that look a little bit better and different. The IPL hand piece has 25% more energy, but these platforms is designed to be able in the future to handle some other hand pieces that we are developing now, which the regular Optimus cannot.
So, this is another platform which is the new platforms. Now, as I have said before, we do not think that these two platforms will cannibalize the first generation, meaning that the Optimus Max will cannibalize the Optimus or the Ignite will cannibalize the body type. It will be over and above, so every doctors who wants to do more with the Morpheus will need to buy one of these two. You cannot use the new Morpheus hand piece on the old generation platforms. So, that will push the doctors to have two or more – two or three different platforms and that’s good for us. In addition, as I said, we are now launching them in the U.S. We are working on regulation in Canada, Europe, Asia and other territories, will take time. As you know, for example in China it takes 2 years to 3 years to get the new platforms on the market.
In Brazil and Visa, it can take the same about year or 1.5 years and we just started. So, it will take few years before these two platforms will be commercially available in all the countries, 96 countries that we are selling today. It’s a process. It’s medical equipment. It’s not fire and forget. You need to train. You need to create clinical data. You need to have training centers. You need to publish. It’s a process that takes few years before the full capacity of those platforms will be exploited. Did I answer the question?
Joseph Stringer: Yes, Oh, absolutely. Yes. That was all very helpful. Thank you. Maybe just one more, I think I heard you discuss that providing loans for certain customers using your cash balances, that’s been going well more or less?
Moshe Mizrahy: No, that’s not what I said. I didn’t say that we are providing loans. I didn’t say that. I said that we had an agreement with leasing companies to help them, limit the risk by creating a pool, pool of money that in some view cases that can help the leasing company, so to enable them to take more risk in the deals that they are helping to finance. I didn’t say that we are financing the customers. We are not. We are not a bank.
Shakil Lakhani: Sure, this is a we put together some programs, risk sharing programs with some listing companies in which – under which we take a fraction of the risk. And in return, they are willing to provide faster approval and basically buy deeper in terms of credit profile of our customers.
Joseph Stringer: Okay. Yes. Okay. That makes much more sense then. I mean that clears up my question. Thank you very much.
Operator: This concludes our question-and-answer session. I would like to turn the call back over to Moshe Mizrahy for any closing remarks.
Moshe Mizrahy: Okay. Thank you everybody. Thank you everybody for joining us. I want to thank all the InMode employees all over the world for continue to work with us. I want to thank especially for the Israeli team that work days and nights during the challenging time that we are having today and maintaining all the activity that basically this company is performing. Thank you again and we will see you again in August.
Operator: The conference is now concluded. Thank you for attending today’s presentation and you may now disconnect.
